The latest Investing Matters Podcast episode with Inclusive Asset Management's Alexandra McGuigan has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHRM.L Regulatory News (PHRM)

  • There is currently no data for PHRM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Operational Update

3 Jul 2015 07:00

RNS Number : 0770S
Phorm Corporation Limited
03 July 2015
 

3 July 2015

 

Phorm Corporation Limited

("Phorm" or the "Company)

 

Operational Update

 

Phorm (AIM: PHRM), a leading internet personalisation technology company, announces an unaudited operational and financial update showing further strong growth in the group's revenues and key performance indicators ("KPIs").

 

RUSSIA

 

Key Performance Indicator

2014 Q3

2014 Q4

2015 Q1

2015 Q2

Average of daily unique users (m)

12.5

23.9

31.5

35.5

Total advertising requests (m)

16,625.3

25,437.3

40,343.5

83,018.9

Total advertisements served (m)

126.9

295.5

342.0

393.3

Total revenues (m RUB)

2.0

9.8

15.7

29.0

 

 

The three core components of the Company's business model are users, inventory (advertising requests) and advertising campaigns (advertisements served). These components are put in place sequentially in order to generate revenue.

 

In terms of users in Russia, the Company is delighted to announce that the average daily unique user numbers has grown from 12.5 million in Q3 2014 to 35.5 million in Q2 2015. These figures serve to demonstrate the scale of the opportunity available to the Company.

 

The number of advertising requests to which the Company has access in Russia has also increased significantly. The number of requests has more than doubled from 40.3 billion in Q1 2015 to 83.1 billion Q2 2015. Phorm now has publishing deals in place with some of the largest players in the market and the Company expects this to continue to grow over the coming months.

 

The most important component of the Company's business model is the advertising campaigns. The growth in both advertisements served and revenues provides evidence of the increasing adoption of Phorm's product in the market. Unaudited revenue derived from Russia has almost doubled, from RUB15.7 million (approximately US$0.3 million) in Q1 2015 to RUB29.0 million (approximately US$0.5 million) in Q2 2015. The growth in revenue is based on demonstrating the performance of the platform to the advertisers through a series of paid for test campaigns. Phorm is now working with six of the top tier global agencies in Russia.

 

Phorm is also delighted to announce that, following these results, five of the agencies have agreed to begin integrating Phorm's platform into their trading desks, which is expected to significantly increase the number of campaigns to which Phorm has access. In addition, two of these agencies have already started integration training. The Company is particularly pleased with this development as it provides rapid access to large numbers of campaigns without having to increase the cost base of our Russian operations.

 

United States of America ("US")

 

Key Performance Indicator

2015 Q2

Average of daily unique users (m)

42.4

Total advertising requests (m)

361,331.8

Total advertisements served (m)

65.9

 

 

The Company announced on 21 April 2015 that is had started commercial operations in the US and has been very pleased with the initial reaction it has received in the market.

 

In terms of users, Phorm has been able to build an audience comparatively quickly and, on average, now has access to 42.4 million daily unique users.

 

The Company has placed significant focus on its ability to integrate with third parties, as it is a route to generating significant commercial scale rapidly. The initial results of this strategy can be seen by the number of advertising requests to which the Company has access. In Q2 2015, Phorm had access to 361.3 billion advertising requests, which is four times more than in Russia and achieved in significantly less time.

 

At this stage, the Company is serving both paid and free test campaigns. There are currently eight campaigns running and Phorm is delighted with the way these initial campaigns are performing and is confident that the majority, if not all, of the free test campaigns will convert to paid-for campaigns in the near future. The pipeline of potential opportunities in the US currently stands at over US$0.5 million and the Company expects this to grow rapidly.

 

As in Russia, the Company will be pursuing a strategy of integrating its technology with the trading desks of the major agencies to quickly access large numbers of campaigns.

 

China

 

In China, as the Company announced on 21 April 2015, the focus has been on developing a partnership with a large local player. A number of these discussions are progressing and further announcements will be made as and when appropriate.

 

 

-Ends-

 

For further information please contact:

Phorm Corporation Limited

Andy Croxson (analysts and investors) +44 20 3397 6001

 

UK Investors

Mirabaud Securities LLP (Broker) +44 20 7321 2508

Jason Woollard

Peter Krens

 

Strand Hanson Limited (Nominated Adviser) +44 20 7409 3494

James Harris

Matthew Chandler

James Dance

 

US Investors

Lippert/Heilshorn and Associates (Investor Relations) +1 212 838 3777

John Heilshorn

 

 

About Phorm

 

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.

 

Phorm's industry leading technology enables its ISP partners to offer a new type of online advertising platform and a free consumer internet content feature, ensuring more relevant advertisements and personalised content for opted-in users.

 

Phorm's advertising platform revolutionises current standards of online privacy, fully protecting the identity of consumers. Phorm's solution is completely opt-in. Only those users consenting to the service are profiled and only ever on an anonymous basis.

 

Phorm's partners include leading ISPs, Publishers, Advertising Networks and Advertisers.

 

Phorm, under a predecessor holding company, was admitted to trading on the AIM market of the London Stock Exchange in 2004.

 

For more information, please visit: www.phorm.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLLLBEDFZBBQ
Date   Source Headline
26th Mar 20145:00 pmRNSIntention to raise £10 million
10th Mar 20147:01 amRNSMemorandum of Understanding with China Telecom
27th Jan 20147:00 amRNSCommercial Launch in China
20th Jan 20147:00 amRNSChange of Adviser
17th Jan 20147:00 amRNSAIM Rule 17 Disclosure Schedule Two (g) Update
6th Jan 20147:00 amRNSExercise of Employee Warrants for Shares
19th Nov 20137:00 amRNSOperational Update for Phorm China
19th Nov 20137:00 amRNSEquity Placing to raise £10 million
13th Nov 20137:12 amRNSStmnt re Share Price Movement
24th Oct 201311:16 amRNSOperations Update
3rd Oct 20137:00 amRNSOperational Launch in China
30th Sep 20137:00 amRNSInterim Results
27th Sep 20137:00 amRNSOperations Update
28th Aug 201312:43 pmRNSAGM Statement
7th Aug 201310:52 amRNSStmnt re Share Price Movement
6th Aug 20137:00 amRNSAGM Statement
26th Jul 20137:00 amRNSTR1: Notification of major interest in shares
26th Jul 20137:00 amRNSTR1: Notification of major interest in shares
17th Jul 20139:20 amRNSIssue of Equity
28th Jun 20137:20 amRNSAnnual Report and Financial Statements
28th Jun 20137:20 amRNSTurkish Operations Update
29th May 20137:00 amRNSFinancing Update
8th May 20138:34 amRNSHolding(s) in Company
23rd Apr 201310:18 amRNSPlacing to raise £7.15 million
21st Mar 20133:20 pmRNSStatement re Share Price Movement
20th Mar 20137:00 amRNSFinancing Update
24th Jan 20137:00 amRNSChinese and Turkish Operations Update
4th Jan 20137:00 amRNSIssue of Shares
18th Dec 20127:00 amRNSIssue of Shares
17th Dec 20127:00 amRNSTurkish Operational Update
13th Dec 20127:00 amRNSTR1: Notification of major interest in shares
21st Nov 201212:33 pmRNSResult of EGM & Admission to trading
6th Nov 201211:50 amRNS£6m Placing, Contract Signature & Turkey Update
16th Oct 20127:00 amRNSCommercial Progress Update
28th Sep 20127:00 amRNSInterim Results
20th Sep 20127:00 amRNSUpdate on Turkey and Phorm China Equity Fundraise
11th Sep 20127:00 amRNSAdmission to Trading
10th Sep 20123:33 pmRNSSch 1 Update - Phorm Corporation Limited
7th Sep 20122:58 pmRNSResults of EGM - Correction
7th Sep 201212:29 pmRNSResults of EGM
5th Sep 20124:15 pmRNSNotification of Major Interests in Shares
31st Aug 20123:49 pmRNSUpdated Appendix to Schedule 1
13th Aug 20129:06 amRNSSchedule 1 - Phorm Corporation Limited
13th Aug 20127:00 amRNSPhorm Re-Domicile of Holding Company from Delaware
2nd Aug 20127:00 amRNSPlacing
9th Jul 20127:00 amRNSCommencement of Commercial Activities with TTNET
3rd Jul 201210:14 amRNSTransfer of Shares
29th Jun 20127:00 amRNSAnnual Financial Report
19th Jun 20126:01 pmRNSCorrection: AGM Result
19th Jun 201211:29 amRNSAGM Result

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.